<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472004</url>
  </required_header>
  <id_info>
    <org_study_id>0753T-101800</org_study_id>
    <secondary_id>B2481004</secondary_id>
    <nct_id>NCT00472004</nct_id>
  </id_info>
  <brief_title>Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women</brief_title>
  <official_title>A Prospective, Randomized, Open Label Study To Compare The Efficacy, Safety And Tolerability Of 17-B Estradiol/Trimegestone CC 1 Mg (Totelle) And Tibolone (Livial) In Postmenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV prospective, randomized, open label, comparative, multicenter study in
      generally healthy postmenopausal women receiving Totelle (17B Estradiol/TMG CC (1mg)) and
      Livial (Tibolone).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased of Vasomotor Symptoms [from baseline to six and twelve months]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Weight (from baseline to six and twelve months)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (from baseline to six and twelve months)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Adherence (from baseline to six and twelve months)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Tenderness (from baseline to six and twelve months)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Vasomotor Symptoms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tibolone 2.5 mg 1 daily, 1 year duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)</intervention_name>
    <description>17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Totelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tibolone (Livial)</intervention_name>
    <description>Tibolone 2.5 mg 1 daily, 1 year duration</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Livial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy postmenopausal women

          -  Last natural (without exogenous hormone therapy) menstrual cycle completed at least 12
             consecutive months prior to screening and without any other kind of gynecological
             bleeding during this same period

          -  At least 1 year of natural occurring amenorrhea

        Exclusion Criteria:

          -  Known or suspected estrogen-dependent neoplasia

          -  Endometrial hyperplasia

          -  Any malignancy with the exception of a history of basal cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>01090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0753T-101800&amp;StudyName=Study%20Comparing%2017B%20Estradiol/TMG%20CC%201mg%20Vs.%20Tibolone%20In%20Postmenopausal%20Women</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>October 28, 2010</last_update_submitted>
  <last_update_submitted_qc>October 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Tibolone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

